454 trials (keyword fallback)
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Brain Neoplasms
Primary: Establish a Safe Dose for Oral 5-ALA Administration — 0; 0; 0; 0 Dose Limiting Toxicity
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants
Brain Tumors · Osteoporosis · Central Nervous System(CNS)Malignancies
Primary: Percent of Patients With Change in Combined Bone Mass Density T-score <= -0.5. — 3.7; 10.5 percentage of patients
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Diffuse Astrocytoma
Primary: Maximum Tolerated Dose of Temsirolimus — 115 mg/week
Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival (PFS) — 25; 28.6 percentage of participants
Glioblastoma Multiforme · Gliosarcoma
Primary: Radiographic Response — 27.8 percentage of participants
Glioblastoma Multiforme
Primary: 6-Month Progression-free Survival — 18.8 percentage of participants
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants
High Grade Glioma · Astrocytoma, Grade III · Glioblastoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of BMX-001 Administered in Combination With Standard RT and TMZ in Newly Diagnosed HGG Patients — NA mg/Participant
Malignant Glioma
Primary: Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity — 5 participants
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-free Survival — .438; .292 proportion of participants
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants